Food and Drug Administration's Research and Evaluation Survey for the Public Education Campaign on Tobacco among LGBT (RESPECT)

ICR 201810-0910-015

OMB: 0910-0808

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2018-12-11
Supporting Statement B
2018-11-14
Supplementary Document
2018-02-21
Supplementary Document
2018-11-14
Supplementary Document
2018-11-14
Supplementary Document
2018-11-14
Supplementary Document
2018-11-14
Supplementary Document
2018-11-14
ICR Details
0910-0808 201810-0910-015
Active 201807-0910-007
HHS/FDA CTP
Food and Drug Administration's Research and Evaluation Survey for the Public Education Campaign on Tobacco among LGBT (RESPECT)
Revision of a currently approved collection   No
Regular
Approved without change 03/22/2019
Retrieve Notice of Action (NOA) 12/12/2018
  Inventory as of this Action Requested Previously Approved
03/31/2022 36 Months From Approved 03/31/2019
23,646 0 21,902
6,566 0 5,856
0 0 0

The Food and Drug Administration (FDA) requests Office of Management and Budget (OMB) approval to conduct in-person and Web-based surveys of lesbian, gay, bisexual, and transgender (LGBT) young adults 18 to 24 years old in the United States, as the Research and Evaluation Survey for the Public Education Campaign on Tobacco among LGBT (RESPECT). These surveys will be fielded for purposes of evaluating FDA’s [LGBT Campaign] public education campaign for LGBT young adults. The primary outcome evaluation will consist of a baseline survey and cross-sectional surveys at six-month intervals following the campaign launch in campaign and control cities. In addition, the cross-sectional surveys will include an embedded longitudinal cohort. Data from this evaluation will be used to gauge campaign awareness and examine the statistical relationships between exposure to the campaign and changes in outcome variables of interest.

PL: Pub.L. 111 - 31 Section 1003(d)(2)(D) Name of Law: Tobacco Control Act
  
None

Not associated with rulemaking

  83 FR 37817 08/02/2018
83 FR 63176 12/07/2018
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 23,646 21,902 0 0 1,744 0
Annual Time Burden (Hours) 6,566 5,856 0 0 710 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
The Food and Drug Administration is submitting this extension request to add a Follow-up 6 to our data collection schedule and refine the data collection documents for Follow-up 6. Follow-Up 6 is scheduled for May 2019 through August 2019. During this follow-up data collection effort, we will continue to re-contact participants and recruit new respondents to offset attrition. The media tracking ICs were removed because they were not needed for the information collection. This led to a decrease in 2,169 responses and 471 hours. The addition of Follow-up 6 increases respondents by 3,913 and burden hours by 1,180.

$8,039,606
Yes Part B of Supporting Statement
    Yes
    No
No
No
No
Uncollected
Amber Sanford 301 796-8867 amber.sanford@fda.hhs.gov

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
12/12/2018


© 2024 OMB.report | Privacy Policy